Acarix Receives UAE Regulatory Approval for CADScor System to Expand Gulf Market Presence
Sweden-based Acarix has received regulatory approval from the Emirates Drug Establishment and the Ministry of Health and Prevention for its CADScor System, a point-of-care diagnostic aid that uses highly sensitive acoustics and advanced computational analysis and AI to assess coronary blood flow and rule out significant coronary artery disease (CAD) in patients presenting with chest pain or shortness of breath. The approval clears the way for commercial availability of the CADScor System across the United Arab Emirates (UAE), marking Acarix’s entry into the Gulf region.
The UAE approval gives Acarix a platform for the wider Gulf Cooperation Council region, where high case volumes and established clinical infrastructure drive demand for tools that improve triage and ease pressure on cardiac imaging and catheterization labs. Acarix will bring the CADScor System to market in the UAE through its commercial partner, UniTech Solutions, which will lead distribution, clinical support, and account development across the region.
Aamir Mahmood, President and CEO of Acarix, said coronary artery disease is a leading health burden across the Gulf, and the diagnostic pathway remains longer and more resource-intensive than it needs to be. Mahmood noted that bringing the CADScor System to the UAE provides frontline clinicians with a fast, non-invasive way to rule out CAD at the point of care, which is important for patients and clinicians.
Beji George, Head of Global Strategy at Acarix, said entering the UAE is a deliberate step in the company’s strategy to establish the CADScor System as a first-line diagnostic aid in high-value markets. George noted that the market has the infrastructure, the case volume, and the appetite for technology that improves the pathway, and it gives Acarix a strong base to build from across the region.
Majed Aboalazm, Chief Executive Officer of UniTech Solutions, said the company is proud to bring the CADScor System to healthcare providers across the UAE. Aboalazm noted that it addresses a clear unmet need, giving clinicians a rapid, reliable way to rule out coronary artery disease early in the pathway, and that UniTech Solutions looks forward to working alongside Acarix to put it into the hands of cardiologists and emergency teams.
